Chronic myeloid leukaemia trials in Germany

In Germany 19 Also abroad 171

19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Erlangen, Frankfurt am Main, Hamburg
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 2Taking people
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
Where
Aachen, Berlin, Chemnitz, Hanover, Jena, Leipzig, Mannheim, Ulm
Age
18 years and over
People
50
Run by
Thomas Ernst, Prof. Dr. med.
See details and how to joinNCT07789574 · EU 2025-523491-23-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
No phaseTaking people
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Where
Altenburg, Amberg, Aschaffenburg, Augsburg, Baden-Baden, Bad Friedrichshall, Bad Liebenwerda, Bad Saarow, Berlin, Bremerhaven, Buchholz Nordheide, Cologne, Cottbus, Deggendorf, Detmold, Donauwörth, Dorfen, Dortmund, Dresden, Düren, Erfurt, Eschweiler, Goslar, Göttingen, Halle, Hanover, Heidenheim, Herrsching am Ammersee, Hildesheim, Kassel, Kempten (Allgäu), Kiel, Landsberg am Lech, Leipzig, Leverkusen, Merseburg, Munich, Mutlangen, Naunhof, Neuss, Offenbach, Offenburg, Oldenburg, Oldenburg in Holstein, Parchim, Potsdam, Regensburg, Rotenburg (Wümme), Saalfeld, Schorndorf, Schwäbisch Hall, Schwetzingen, Soest, Solingen, Stade, Torgau, Twistringen, Ulm, Wesel, Wetzlar, Winnenden, Zittau
Age
18 years to 100 years
People
380
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07549516
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Berlin, Munich, Ulm
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1/2Taking people
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Where
Aachen, Berlin, Frankfurt Am Main, Hanover, Jena, Mannheim, Munich
Age
18 years to 64 years
People
330 worldwide
Run by
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 1/2Taking people
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Where
Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
Age
18 years and over
People
38
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Aachen, Freiburg im Breisgau, Lübeck, Mannheim
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Where
Berlin, Dresden, Leipzig
Age
18 years and over
People
333 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00
Phase 2Not yet taking people in Germany
Asciminib Frontline Risk Adapted
Where
Jena
Age
18 years and over
People
200
Run by
Prof. Dr. med. Andreas Hochhaus
See details and how to joinNCT07804901 · EU 2026-528103-13-00
Phase 2Taking people
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
Where
Dresden, Erlangen, Essen, Frankfurt Am Main, Hamburg
Age
Up to 17 years
People
16 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522138-29-00 · EU 2025-522138-29-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Brunswick, Luebeck
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Germany
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 1Taking people
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Where
Aachen, Berlin, Frankfurt Am Main, Homburg, Jena, Mannheim, Rostock
Age
18 years and over
People
250 worldwide
Run by
Enliven Therapeutics
See details and how to joinNCT05304377 · EU 2023-503335-18-00
Phase 1Enrolling by invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Where
Berlin, Dresden, Marburg, Munich, Ulm
Age
18 years and over
People
178
Run by
AvenCell Therapeutics, Inc.
See details and how to joinNCT07474051 · EU 2025-521717-67-00
Phase 1/2Taking people
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Where
Berlin, Brunswick, Leipzig
Age
18 years and over
People
240 worldwide
Run by
Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00
No phaseTaking people
International Chronic Myeloid Leukemia Pediatric Study
Where
Dresden
Age
Up to 18 years
People
750 worldwide
Run by
Poitiers University Hospital
See details and how to joinNCT01281735